Oryzon to provide corporate progress updates at several events in May

Oryzon Genomics S.A., a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today that its management will give an update on corporate progress at several international events in May. 

Oryzon will attend Bio-Equity Europe 2024, which will be held at the Kursaal Elkargunea Center in San Sebastián (Spain) on May 12-14. The company will provide a corporate update on May 13 at 15:15 CET and will hold one-on-one meetings with global investors and pharmaceutical companies. Click on the link for more info about Bio-Equity Europe 2024 

Oryzon has been invited to attend Asebio Investor Day 2024, an investor event organized by Asebio, the Spanish Bioindustry Association, which will take place at the Kursaal Elkargunea Center in San Sebastián (Spain) on May 15. Oryzon will participate in a panel entitled “Alternative secondary markets. Providing liquidity to investors” at 12:45 CET and will maintain meetings with investors. Click on the link for more info about Asebio Investor Day 2024 

Oryzon has been invited to present at the RSC Hot Topics: Covalent Drug Discovery 2024 conference, organized by the Royal Society of Chemistry, which will take place online on May 16. Dr. Tamara Maes, Chairman of Oryzon’s Scientific Advisory Board, will give a presentation entitled “Mechanism of action and therapeutic potential of covalent LSD1 inhibitors” at 14:30 BST. Click on the link for more info about RSC Hot Topics Covalent Drug 2024 

Oryzon will attend the Foro Medcap BME 2024, which will be held at the Madrid Stock Exchange Palace in Madrid (Spain) on May 28-30. Oryzon will hold one-on-one meetings with Spanish and international investors. Click on the link for more info about Foro Medcap 2024